Previous 10 | Next 10 |
2024-05-14 16:44:07 ET Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference May 14, 2024, 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Citizens JMP Presentation Roy Bu...
2024-05-13 21:45:14 ET Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q1 2024 Earnings Call May 13, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call ...
2024-05-13 19:47:09 ET Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Conference Call May 13, 2024, 04:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Me...
2024-05-13 18:00:04 ET Sudan Loganathan from Stephens issued a price target of $20.00 for INO on 2024-05-13 16:32:00. The adjusted price target was set to $20.00. At the time of the announcement, INO was trading at $11.36. The overall price target consensus is at $4.00 w...
2024-05-13 16:07:13 ET More on Inovio Pharmaceuticals Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation Inovio Pharmaceuticals: The Dilution Continues Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript Inovi...
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papilloma...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Q1 2024 revenue of $45.0 million Q1 2024 GAAP Net Loss of $4.5 million and positive Adjusted EBITDA of $3.8 million Fifth consecutive quarter of positive Adjusted EBITDA Inseego Corp. (Nasdaq: INSG) (the “Company”), a technology leader in 5G mobile and ...
2024-05-05 08:54:00 ET Some investors might remember Inovio Pharmaceuticals (NASDAQ: INO) ; others might not. The small-cap biotech was once racing to develop an effective coronavirus vaccine. Its bet to become a leader in this field fell flat, the company largely fell into irreleva...
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat a...
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
2024-07-16 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today announced that the company will release its financial results for the second quarter of 2024, ended June 30, 2024, after the financial ...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respi...